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Available online 21 November 2015Neutrophil chemotaxis is involved in the lung inﬂammatory process in conditions such as chronic obstructive
pulmonary disease (COPD). Neutrophil elastase (NE), one of the main proteases produced by neutrophils, has
an important role in the inﬂammatory process via the release of chemokines from airway epithelial cells. It
was recently shown that roﬂumilast N-oxide has therapeutic potential in COPD. The aim of the present study
was to investigate roﬂumilast N-oxide's effect on NE-induced chemokine production and signaling pathways
in A549 epithelial cells.
A549 cells were incubated with NE for 30 min, washed with PBS and then cultured for 2 h (for measurement of
mRNA expression) and 24h (for chemokine release) or for 5 to 30min (for protein phosphorylation assays). Prior
to the addition of NE, cells were also pre-incubatedwith prostaglandin E2 (PGE2), alone and in combination with
roﬂumilast N-oxide.
Addition of NE was associated with elevated chemokine production by A549 cells and induction of the p38α
pathway. In contrast when combined with PGE2, the roﬂumilast N-oxide had an additive effect on the inhibition
of NE-induced chemokine release and p38α and other kinases activation.
In conclusion, we demonstrated that NE is able to increase the release of chemokines from epithelial cells via the
activation of p38αMAP-kinase and that roﬂumilast N-oxide when combined with PGE2 lowers NE-induced ki-
nase activation and chemokine production.





In the respiratory tract, neutrophils have amajor role in inﬂammato-
ry conditions, such as chronic obstructive pulmonary disease (COPD)
[1]. Neutrophil elastase (NE), one of the major proteases produced by
neutrophils, is a serine protease involved in host defense against bacte-
rial pathogens [2]. Extracellular NE activity is regulated by a number of
endogenous protease inhibitors, including α1-antitrypsin, secretory
leukoprotease inhibitor andα2-macroglobulin [3].When the extracellu-
lar concentration of free NE exceeds the buffering capacity provided by
endogenous inhibitors, the elastase starts to drive inﬂammatory pro-
cesses in the lung. Hence, elevated concentration of active proteinases
degrades the protein components of the extracellular matrix, which
leads to destruction of the alveolar walls and thus airspace enlargementilidade e criopreservação (HLA-
rneiro). Bairro: São Francisco
i).[4]. In COPD, elevated levels of NE and low levels of endogenous
antiproteases in bronchoalveolar lavage (BAL) ﬂuid are correlated
with the severity of emphysema [5]. Neutrophil elastase's elastolytic ac-
tivity thus has a role in lung inﬂammation via the release of pro-
inﬂammatory mediators from airway epithelial cells [6]. Besides its di-
rect elastolytic activity, NE releases soluble epidermal growth factor re-
ceptor (EGFR) ligands and initiates EGFR/MEK/ERK signaling [7].
Furthermore, NE's actions activate the Toll-like receptor 4 (TLR-4)/
MyD88/TRAF6/NF-κB or/and PKC/EGFR/ERK signal transduction
pathways and lead to IL-8/CXCL8 release and mucin5AC expression
in epithelial cells [8,9]. In animal models, genetic deﬁciency or
pharmacological intervention with small-molecule or physiological in-
hibitors of NE affords signiﬁcant protection (i.e. a reduction of approxi-
mately 60%) against the pro-inﬂammatory and emphysematous effects
of chronic exposure to cigarette smoke [10,11].
It was recently reported that phosphodiesterase 4 (PDE4) inhibitors
have therapeutic value in treating exacerbations of COPD [12,13]. By
preventing the degradation of cAMP, PDE4 inhibitors enhance the
anti-inﬂammatory action of this secondary messenger. Epithelial cells
2 T. Victoni et al. / International Immunopharmacology 30 (2016) 1–8in the lung and airways express PDE4 [14]. The inhibitory effect of
PDE4 inhibitors on the release of cytokines and chemokines in vitro
and in vivo was recently reviewed [15]. Roﬂumilast and its metabo-
lite roﬂumilast N-oxide (RNO) are known to reduce the lipopolysac-
charide (LPS)-induced release of CCL-2,-3,-4, CXCL10 and tumor
necrosis factors (TNF)-α from human lung parenchyma, human pul-
monary macrophages and monocyte-derived macrophages [16,17,
18]. We recently demonstrated that RNO is able to reduce the pro-
duction of cytokines and chemokines from A549 epithelial cells stim-
ulated with cigarette smoke extract [19]. However, RNO's effect on
NE-activated epithelial cells has not yet been investigated. The ob-
jective of the present study was to investigate RNO's effect on NE-
induced cytokine/chemokine production and signaling pathway ac-
tivation in A549 epithelial cells.
2. Materials and methods
2.1. Reagents
Roﬂumilast-N-oxide was provided by Nycomed (Konstanz,
Germany). Human NE was obtained from Biocentrum (Krakow,
Poland). F-12K Nutrient Mixture (Kaighn's Modiﬁcation) cell culture
medium, antibiotics, glutamine and trypsin-EDTA were purchased
from Invitrogen (Eugene, OR, USA). Fetal calf serum (FCS) was obtained
fromHyclone (Logan, UT, USA). Lipolysaccharide from E. coli 055:B5, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
and the EGFR inhibitor AG-1478 were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Speciﬁc antibodies against phospho-(p44/42)
ERK1/2, (p44/42) ERK1/2, phospho-p38α MAP kinase, p38α MAP ki-
nase, phospho-SAPK/JNK and SAPK/JNK were from Cell Signaling Tech-
nology (Beverly, MA, USA). Acrylamide, SDS, Tris, HEPES, and bovine
serum albumin (BSA) were from Eurobio (Les Ulis, France). A Bradford
protein assay and Precision Plus Protein Dual Color Standardswere pur-
chased from Bio-Rad (Hercules, CA, USA).
2.2. Cell culture
The human alveolar epithelial cell line (A549) was purchased from
American Type Culture Collection (Manassas, VA, USA) and cultured in
F-12K supplemented with 10% FCS, 10 units/mL penicillin, 10 μg/mL
streptomycin, 2 mM L-glutamine and 10 mM HEPES at 37 °C and with
5% CO2. For the experiments, aliquots of 1 × 105 cells were transferred
to 24-well plates and grown to conﬂuence.
2.3. Treatments
A549 cellswerewashed and cultured overnight in serum-free F-12K
medium supplemented with antibiotics, L-glutamine and HEPES. The
starved cells were incubated with NE for 30 min or vehicle (PBS),
washed with PBS and then cultured in serum free F-12 K. After stimula-
tion, cell supernatants were collected at 24 h (for cytokine measure-
ments) and cell pellets were collected after 2 h (for mRNA expression
analysis). Alternatively, A549 cells were pre-incubated for 2 h with
PGE2 (10 nM) alone or in combination with RNO (at 0.1 μM, 0.3 μM
and 1 μM), vehicle (DMSO 0.01%) or EGFR inhibitor AG-1478 prior to
the addition of NE. All experiments were performed in serum-free me-
dium in triplicate and were repeated at least three times. At the end of
the incubation period, culture supernatants were harvested and stored
at−80 °C until further analysis.
2.4. Measurement of chemokine protein and mRNA levels
The concentrations of IL-8/CXCL8, MCP-1/CCL2, Gro-α/CXCL1 in the
culture supernatants were measured using ELISAs (R&D Systems,
Abingdon, UK). Total RNAwas isolated fromA549 cells using a commer-
cially available kit (Promega, Madison, WI, USA). RNA quantity andpurity were assessed with a Nanodrop ND-1000 spectrophotometer
(Nyxor Biotech, Paris, France). Total RNA (1 μg) was reverse-
transcribed into cDNA using the High-Capacity cDNA Archive Kit (Ap-
plied Biosystems, Foster City, CA). Real-time, quantitative RT-PCR was
performed with the SYBR Green ﬂuorescent dye methodology (SYBR
Green PCR Master Mix, Applied Biosystems) and the StepOnePlus™
real-time PCR system (Applied Biosystems). Primer pairs for each tran-
script were chosen with NCBI software (http://www.ncbi.nlm.nih.gov),
as follows. IL-8/CXCL8: forward 5′-AAG AAA CCA CCG GAA GGA AC-3′,
reverse 5′-AAA TTT GGG GTG GAA AGG TT-3′; MCP-1/CCL2: forward
5′-TGT CCC AAA GAA GCT GTG ATC-3′, reverse 5′-ATT CTT GGG TTG
TGG AGT GAG-3′; Gro-α/CXCL1: forward 5′-AAC CGA AGT CAT AGC
CAC AC-3′, reverse 5'CCT CCC TTC TGG TCA GTT G3’; GAPDH: forward
5′-GGC ATG GAC TGT GGT CAT GAG-3′, reverse 5′-TGC ACC ACC AAC
TGC TTA GC-3′. Ampliﬁcation curves were analyzed according to the
comparative cycle threshold method, using StepOne software (version
2.1, Applied Biosystems). The steady-state mRNA levels for the genes
of interest were normalized against those of GAPDH.2.5. Evaluation of protein kinase phosphorylation by Western blotting
A549 cells were incubated with medium alone, PBS and NE for 5, 15
and 30min. Next, the cellswerewashedwith PBS and lysed in lysis buff-
er (Novagen, San Diego, CA, USA) containing protease inhibitor cocktail
and phosphatase inhibitor cocktail (Roche, Mannheim, Germany) on ice
for 15min. Equal amounts of cell lysate (40 μg) were separated on 5% or
10% SDS-PAGE gels and then transferred onto nitrocellulose mem-
branes. The membranes were blocked for 1 h with 5% BSA or 5% w/v
non-fat powdered milk in TBS containing 0.1% Tween 20. Next, the
membranes were incubatedwith amousemonoclonal antibody against
phospho-p44/42 ERK1/2 (1/2000), a rabbit monoclonal antibody
against total-p44/42 ERK1/2 (1/1000), a rabbit monoclonal antibody
against phospho-STAT3 (1/1000), a rabbit monoclonal antibody against
total-STAT3 (1/1000), a rabbit monoclonal antibody against phospho-
p38α MAP Kinase, a rabbit monoclonal antibody against total-p38α
MAP (1/1000), a mouse monoclonal antibody against phospho-SAPK/
JNK (1/1000), or a rabbit monoclonal antibody against total SAPK/JNK
(1/1,1000) for 2 h at room temperature. After washing, the membranes
were incubated for 2 h with a horseradish-peroxidase-conjugated anti-
mouse/rabbit antibody. The blots were then incubated with an en-
hanced chemiluminescence solution for 1 min. Light production
was quantiﬁed with a charge-coupled device camera. Protein levels
of kinase were analyzed by densitometry using BIO-1D software
(Vilbert, Marne-la-Valleé, France). Phosphorylation of (T180/Y182)
p38α MAPK was conﬁrmed quantiﬁed with a speciﬁc ELISA (R&D
Systems).2.6. Human phosphoprotein array
Cells were also pre-incubated with PGE2 (10 nM) alone or in combi-
nation with RNO (1 μM) for 2 h before the addition of NE. Cell lysates
(500 μg of total protein per array) were applied to the phosphoprotein
array (the Proteome Proﬁler Human Phosphokinase Array Kit, R&D Sys-
tems) according to the manufacturer's instructions.2.7. The MTT cell viability assay
Neutrophil elastase's cytotoxicity for A549 cells was checked with
the MTT cell viability assay. Cell cultures were incubated with MTT
(ﬁnal concentration: 0.5 mg/mL) at 37 °C for 2 h. The formazan reaction
product was extracted in dimethylsulfoxide (DMSO) and the OD was
measured spectrophotometrically at 570 nm (with DMSO as a blank).
Cell viability was expressed as a percentage of the value observed
with untreated cells.
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The results are expressed below as the mean ± S.E.M. A one-way
analysis of variance (ANOVA) was used to assess between-group treat-
ment effects. Treatment interactions were compared in a Tukey post-
test. In all analyses, the threshold for statistical signiﬁcance was set to
P b 0.05.
3. Results
3.1. The effect of NE on the production of IL-8/CXCL8, Gro-α/CXCL1 and
MCP-1/CCL2 by A549 cells
Incubation of A549 epithelial cells with NE (10 nM) was associated
with signiﬁcantly greater release of IL-8/CXCL8, MCP1/CCL2 and Gro-
α/CXCL1 (Fig. 1A, B and C). Lower (1 nM) or higher (50 or 100 nM) con-
centrations of NE were not able to increase the levels of chemokine. In-
deed, the highest tested concentration of NE (100 nM) was cytotoxic
(Fig 1D). Hence, a concentration of 10 nMwas selected for investigation
of NE's effects on chemokinemRNA expression; NEwas associatedwith
signiﬁcantly greater mRNA expression for IL-8/CXCL8, MCP1/CCL2 and
Gro-α/CXCL1 at 2 h (Fig. 2A, B and C).
3.2. Effects of the EGFR inhibitor AG-1478 on NE-induced release of chemo-
kine by A549 cells
Given that the EGFR is known to be activated by NE, we next sought
to determinewhether EGFR inhibitors could inhibit chemokine produc-
tion from A549 cells. The incubation of epithelial cells with AG-1478 (at
0.1 μM, 0.3 μMand 1 μM)was associatedwith concentration-dependent
inhibition of the release of IL-8/CXCL8 (Fig. 3A). Moreover, AG-1478 at
0.3 μM or 1 μM inhibited the NE-induced release of Gro-α/CXCL1
(Fig. 3C) but not the release of MCP1/CCL2 (Fig 3B).Fig. 1. Effects of NE on IL-8/CXCL8, Gro-α/CXCL1 andMCP-1/CCL2 release and cell viability (in a
or different concentrations of NE (1 nM-100 nM) for 30 min and then with medium alone for
measured by ELISA (A, B, and C) and cell viability was determined with an MTT assay (D). The
with the control.3.3. Effects of a combination of RNO and PGE2 on NE-induced chemokine re-
lease by A549 epithelial cells
Roﬂumilast N-oxide alone had no effect on NE-induced chemokine
release (data not shown). In contrast, the combination of RNO with
10 nM PGE2 decreases IL-8/CXCL8, MCP1/CCL2 and Gro-α/CXCL1 re-
lease. The incubation of epithelial cells with PGE2 alone is able to de-
crease of NE-induced IL-8/CXCL8, MCP1/CCL2 and Gro-α/CXCL1
release (Fig. 4A, B and C), however the combination of RNO with
10 nM PGE2, further reduced the release of MCP1/CCL2 and Gro-α/
CXCL1 (Fig. 4B and C) with respect to PGE2.
3.4. Effects of NE on the activation of signaling pathways
Mitogen-activated protein kinases are involved in a number of pro-
cesses (such as oxidative stress and inﬂammation), and p38α is report-
edly induced by NE. The time-dependent phosphorylation of ERK, JNK
and p38α mitogen-activated protein (MAPK) kinases was monitored
following NE stimulation. Signiﬁcantly greater p38αMAPK activation
was observed 5 min after NE treatment but not after 15 or 30 min
(Fig. 5A and E). In contrast, NE did not activate the JNK, ERK 1/2 and
STAT3 pathways (Fig. 5B, C, and D). Total levels of p38α, JNK, ERK 1/2
and STAT3 were not altered by NE treatment, relative to control exper-
iments (Fig. 5A, B, C, and D).
3.5. Activation of the p38α kinase pathway by NE is less intense after treat-
ment with RNO
The treatment of epithelial cells with 10 nM PGE2 (whether alone or
in combinationwith RNO)markedly reduced theNE-induced activation
of p38α kinase after 5 min (Fig 6A). However, only the combination of
RNO and PGE2 was associated with signiﬁcantly lower p38α activation
(Fig. 6A). This ﬁnding was conﬁrmed by the results of a speciﬁc ELISAnMTT assay). Serum-starved A549 cells were incubatedwithmedium alone (control), PBS
24 h. After collection of the culture supernatants, the concentrations of chemokines were
data represent the mean ± S.E.M of 6–10 independent experiments. *P b 0.05, compared
Fig. 2. Effects of NE on mRNA expression for IL-8/CXCL8, Gro-α/CXCL1 and MCP-1/CCL2. Serum-starved A549 cells were incubated with medium alone (control), PBS or NE (10 nM) for
30min and thenwithmediumalone for 2 h.mRNA expressionwas determinedby real-time quantitative RT-PCR. The geneexpression results are normalized against the values forGAPDH.
The data represent the mean ± S.E.M of four independent experiments. *P b 0.05, compared with the control.
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with RNO, PGE2 did not alter the activation of ERK 1/2 and JNKpathways
or the total amount of protein (Supplementary Fig. 1).
3.6. Effects of RNO on NE-induced protein phosphorylation in A549 cells
We ﬁrst used a human phosphoprotein array kit to establish wheth-
er or not other signaling pathways were activated by NE 10 nM in A549
cells pre-treated with PGE2. We then analyzed the effects of a combina-
tion of RNO and PGE2, relative to PGE2 alone. After the pre-treatment of
A549 cellswith PGE2, incubationwithNEwas associatedwith activation
(an increase of 30% compared to the control was considered) of 12 ki-
nases (gray bars; RSK 1/2/3, c-Jun, Akt T308, Hck, Fak, STAT5 a/b, p53
S46, p70 S6, PLC-γ1, Chk2, Pyk2, and PRAS 40 t) of the 45 tested
(Fig. 7A). Of the 12 kinases activated by NE in the presence of PGE2,
ﬁve (blanc bars; Hck, FAK, STAT5 a/b, P70s6 and CHK-2) appeared to
be less strongly activated when PGE2 was combined with 1 μM RNO
(Fig. 7A and B).
4. Discussion
In the present study, we investigated the anti-inﬂammatory effects
of RNO (a PDE type 4 inhibitor) on NE-induced changes in the A549 al-
veolar epithelial cell line. We found that NE raises the production of
three chemokines by these epithelial cells and that this effect is mediat-
ed by the p38α signaling pathway. An EGFR inhibitor lowered the NE-
induced release of IL-8/CXCL8 and Gro-α/CXCL1 (but not of MCP-1/Fig. 3. Effects of AG-1478 on the NE-induced release of chemokines by A549 cells. Serum-starve
(10 nM) for 30 min, and were then incubated with medium alone for 24 h. The culture supern
data represent the mean ± S.E.M of three independent experiments. #P b 0.05, compared withCCL2). When combined with PGE2, RNO had a more marked inhibitory
effect on chemokine release and p38α kinase activation. RNO also
inhibited ﬁve other NE-induced kinases.
Previous studies have found that smokers (particularly those suffer-
ing from COPD) have high neutrophil counts in the airways [5]. Other
literature data have shown that the NE produced by neutrophils causes
the release of cytokines and chemokines from airway epithelial cells [6,
9,20]. In the present study, NE induced the release of IL-8/CXCL8, MCP-
1/CCl2 and Gro-α/CXCL1 and greater chemokine mRNA expression by
A549 cells. Elevated levels of these chemokines are found in the BAL
ﬂuid from COPD patients, and are involved in the physiopathology of
COPD [21]. We also found that chemokine release was greatest at
10 nM NE, with less release at higher concentrations of the enzyme.
This paradoxical effect may be due to proteolysis of the chemokines
byNE [20]. Indeed,we found that 50 nMNEwas associatedwithdetach-
ment of about 10% of the cells (data not shown). In vivo, the activity of
NE is controlled by endogenous inhibitors (such as α1-proteinase, se-
cretory leukoprotease inhibitor and elaﬁn). The absence of these inhib-
itors in vitro may explain why NE is active at low concentrations [5].
It has been reported that NE-induced release of IL-8/CXCL8 from
bronchial epithelial cells can be prevented by speciﬁc inhibitors, sug-
gesting that chemokine release involves NE's proteolytic activity (via
the activation of surface receptors such as TLR-4 and EGFR) [6,7]. In-
deed, the NE protease cleaves the cytoplasmic membrane protein
meprin-α, which in turn activates TLR-4 and EGFR and leads to the pro-
duction of CXCL8/IL8 via the NFk-B and MAP kinase pathways. Bergin
and colleagues (2008) showed that TLR-4 inhibitors can inhibit NE-d A549 cells were incubated with AG-1478 or vehicle 30min prior to stimulation with NE
atants were collected and the concentrations of chemokines were measured by ELISA. The
vehicle.
Fig. 4. Effects of PGE2 in the presence and absence of RNOonNE-induced IL-8/CXCL8, Gro-α/CXCL1 andMCP-1/CCL2 release byA549 cells. Cellswerepre-incubatedwith 10nMPGE2 alone
or in combination with RNO (0.1 μM; 0.3 μMor 1 μM) or vehicle for 2 h and were then stimulatedwith NE for 30 min. After 24 h, cell culture supernatants were collected and the levels of
chemokineswere quantiﬁed by ELISA. Results are expressed as themean± S.E.M of four independent experiments. αP b 0.05, comparedwith NE (10 nM), #P b 0.05, comparedwith PGE2.
Fig. 5. Effects of NE on ERK1/2, p38α and JNK kinase in A549 cells. Serum-starved A549 cells were incubated with serum free medium alone (the control), PBS or NE 10 nM for 5, 15 or
30 min. Total cell lysates were immunoblotted with antibodies speciﬁc for phospho-p38α kinase and total p38α kinase (A), phospho-JNK and total JNK (B), phospho ERK1/2 and total
ERK1/2 (C) and phospho-STAT3 and total STAT3 (D). Densitometry of the phospho-p38α kinase (E), phospho-JNK (F), phospho ERK1/2 (G), phospho STAT3 (H) blots. Results are
expressed as the mean ± S.E.M of three independent experiments, *P b 0.05, compared with the control.
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Fig. 6. Effects of PGE2 in the presence and absence of RNO on NE-induced activation of the p38α pathway. Serum-starved A549 cells were incubatedwith PGE2 alone or in the presence of
RNO and were then stimulated with PBS or 10 nMNE for 5 min. Total cell lysates were immunoblotted with antibodies speciﬁc for phospho-p38α kinase and total p38α kinase (A). The
amount of phosphorylatedp38α in the cell lysatewas determinedby ELISA (B). Results are expressed as themean±S.E.M of three independent experiments. Statistically signiﬁcant p38α
phosphorylation was detected using the Mann–Whitney U–test. *P b 0.05, compared with the PBS. αP b 0.05, compared with NE (10 nM).
Fig. 7. Effects of RNO, in the presence PGE2, on NE-induced protein phosphorylation in A549 cells. Cells were pre-incubated for 2 h with PGE2 (10 nM) alone or in the presence of RNO
(1 μM) and were then stimulated 5 min with 10 nM NE. Cell extracts were probed on human phosphoprotein arrays. Results representing the signal intensity (in arbitrary units) were
expressed as a percentage of the control value (serum-free medium alone).
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[22]. However, the activation of the cells with a combination of NE and
low concentrations of LPS (to directly co-activate TLR-4) was not asso-
ciated with greater chemokine release (data not shown). Devaney and
colleagues (2003) suggested that NEmay induce tolerance to LPS in ep-
ithelial cells by decreasing TLR-4 expression [23]. Then, we looked at
whether or not 10 nM NE could alter the TLR-4 expression. However,
no changes were observed two hours after 30 min of treatment with
NE (data not shown).
Studies of bronchial epithelial cells also reported that transcription
of the IL-8/CXCL8 genes and release of the corresponding proteins
were dependent on transient activation of EGFR [6]. We showed that
NE-induced IL-8/CXCL8 andGro-α/CXCL1 release depends on activation
of the EGFR, since AG-1478 reduced the release of these chemokines.
Our ﬁndings are consistent with lower levels of NE-induced IL-8/
CXCL8 release observed after treatment of A549 cells with an EGFR in-
hibitor [6]. The absence of an effect of AG-1478 on NE-induced release
of MCP-1/CCL2 may suggest that an alternative pathway is involved
for this chemokine.
Neutrophil elastase may also activate MAP kinases (namely ERK and
p38). TheNE-induced expression of the gene coding for IL-8/CXCL8may
be regulated by NF-kB and p38αMAP kinase [6,24]. Our results suggest
that the NE-induced elevation in the production of IL-8/CXCL8 by A549
cells involves the p38α signaling pathway. No JNK activation and a low
degree of ERK activation were observed after NE treatment, suggesting
that other pathways are involved in NE-induced chemokine release. In-
deed, STAT3 can be activated by EGFR [25], although NE did not activate
STAT 3 in our experiments on the A549 cell line.
It was recently conﬁrmed that roﬂumilast has therapeutic value in
treating exacerbations of COPD [13,26]. The effect of roﬂumilast on the
NE-induced release of chemokines and kinases activation in has not pre-
viously been described.We therefore decided to investigate the effect of
RNO (the activemetabolite of roﬂumilast) on theNE-induced activation
of A549 cells. Our results show that RNO is able to reinforce PGE2's in-
hibitory effect on NE-induced chemokine production. In this in vitro
model, PGE2 was needed to activate adenylate cyclase because the
A549 epithelial cell line does not produce endogenous cAMP [27]. By in-
creasing levels of cAMP, PGE2 reduces chemokine release and p38α ac-
tivation. However, a combination of RNO and PGE2 exerted a more
marked inhibitory effect than PGE2 alone. We next looked at whether
RNO exerted inhibitory effects on other kinases (i.e. those not affected
by PGE2 alone). In the presence of PGE2, RNO prevented the phosphor-
ylation of ﬁve protein kinases (at least 50% after treatment with
Roﬂumilast n-oxide in relation to the untreated group): Hck, Fak, STAT
5a/b, p70 S6 andCHK-2 (Fig. 7). Our results are in linewith the literature
data on RNO effects on kinase phosphorylation and cytokine release by
bronchial epithelial cells and macrophages [18,28].
Hck is amember of the Src family of tyrosine kinases. Several studies
have shown that Hck is involved in inﬂammatory signaling pathways.
Indeed, Ziegle and colleagues (1988) observed that LPS-mediated mac-
rophage activationwas associated with elevated expression of Hck [29].
STAT5 activation may be involved in cytokine production by A549 cells
after EGF stimulation [30]. We showed that NE-induced several differ-
ent kinases, that can been involved in cytokines release. Then, the ef-
fects of RNO in others kinases (Hck, Fak, STAT 5a/b, p70 Chk-2)
activation needs to be further investigated, as perhaps its inhibition
may be involved in the release of cytokines in COPD context. Taken as
a whole, our ﬁndings suggest that RNO's anti-inﬂammatory effect is
complex and involves several kinases and pathways.
5. Conclusions
We found that NE is able to increase the release of chemokines from
epithelial cells via the activation of p38α MAP-kinase. Moreover, we
showed that an EGF receptor inhibitor is able to inhibit NE-induced pro-
duction of IL-8/CXCL8 and Gro-α/CXCL1 but not of MCP-1/CCL2. Incontrast, treatment of the cells with a combination of RNO and PGE2
was associated with lower IL-8/CXCL8, MCP-1/CCl2 and Gro-α/CXCL1
release and a lower degree of activation of several kinases. Our results
conﬁrm RNO's anti-inﬂammatory effect in this in vitro elastolytic
model and help to explain the compound's mechanism of action.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.intimp.2015.11.019.
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